1.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00012, NCT00372788
|
|
2.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00008, NCT00372944
|
|
3.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: NCI-2009-00604, U10CA027469, CDR0000563965, GOG-0239, NCT00551070
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00247, MCC#15260, CDR0000571751, N01CM62207, N01CM62208, MCC-07-0973, 7909, GCRC-2625-ORC, VU-VICC-GI-0726, 77782, NCT00550719
|
|
5.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00251, 07056, N01OH62207, CDR0000573452, OSU-07056, 7932, NCT00553332
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MCC-15305, MCC-15305, MCC-LOI-7918, 7918, NCT00559949
|
|
7.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00250, N01CM62209, N01CM62201, CDR0000581297, 15455B, UCCRC-15455B, 7925, NCT00588809
|
|
8.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-09003, 09-003, 8252, NCT00866177
|
|
9.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 09-005, NCT00888134
|
|
10.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00016, NCT00890825
|
|
11.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00006, NCT00936221
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0229H, GOG-0229H, NCT01011933
|
|
13.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MCC-16137, 24918/1, NCI-8631, NCT01085214
|
|
14.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D9010C00009, AGICC 09CRC02, NCT01116271
|
|
15.
|
Phase: Phase II Type: Tissue collection/Repository, Treatment Status: Temporarily closed Age: Postmenopausal Sponsor: Other Protocol IDs: SAKK 21/08, SWS-SAKK-21/08, EUDRACT-2010-019965-27, EU-21046, CDR0000680800, NCT01160718
|
|
16.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MCC-16066, NCI-P-8436, NCT01166126
|
|
17.
|
Phase: Phase II Type: Treatment Status: Closed Age: 16 and over Sponsor: Other Protocol IDs: OCTO_015, NCT01256359
|
|
18.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00005, NCT00463814
|
|
19.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00004, NCT00600496
|
|
20.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D1532C00020, 2007-004456-37 EudraCT Number, NCT00710515
|